Probability discounting of treatment decisions in multiple sclerosis: associations with disease knowledge, neuropsychiatric status, and adherence
Patients weigh risks and benefits when making treatment decisions. Despite this, relatively few studies examine the behavioral patterns underpinning these decisions. Moreover, individual differences in these patterns remain largely unexplored.
The purpose of this study was to test a probability discounting model to explain the independent influences of risks and benefits when patients make hypothetical treatment decisions. Furthermore, we examine how individual differences in this probability discounting function are associated with patient demographics, clinical characteristics, disease knowledge, neuropsychiatric status, and adherence.
Two hundred eight participants with relapsing-remitting multiple sclerosis (MS) indicated their likelihood (0–100%) of taking a hypothetical medication as the probability of mild side effects (11 values from .1 to 99.9%) and reported medication efficacies (11 values from .1 to 99.9%) varied systematically. They also completed a series of questionnaires and cognitive tests.
Individual components of medication treatment decision making were successfully described with a probability discounting model. High rates of discounting based on risks were associated with poor treatment adherence and less disease-specific knowledge. In contrast, high rates of discounting of benefits was associated with poorer cognitive functioning. Regression models indicated that risk discounting predicted unique variance in treatment adherence.
Insights gained from the present study represent an important early step in understanding individual differences associated with medical decision making in MS. Future research may wish to use this knowledge to inform the development of empirically supported adherence interventions.
KeywordsMultiple sclerosis Adherence Probability discounting Disease-modifying therapy Medical decision making
This research was funded by a grant from the National Multiple Sclerosis Society to the first author (HC-1411-01993).
Compliance with ethical standards
This study was approved by the University of Missouri-Kansas City Institutional Review Board and the University of Kansas Medical Center Human Subjects Committee.
Dr. J. Bruce provides non-branded talks for Novartis, is a part-time employee of the National Hockey League, does consulting for Princeton University’s Department of Athletic Medicine, and is a consultant to Major League Soccer’s Sporting KC.
Dr. Sharon Lynch has participated in multi-center drug trials through Novartis, Teva, Biogen, Sanofi, Genzyme, Genentech, Roche, NMSS and NIH, Alexion, Opexa, Sun Pharma, Vaccinex, Actelion, and Mallinkrodt.
- Berry MS, Johnson PS, Collado A, Loya JM, Yi R, Johnson MW (2018) Sexual probability discounting: a mechanism for sexually transmitted infection among undergraduate students. Arch Sex BehavGoogle Scholar
- Bosworth H (2006) Medication treatment adherence. In: Bosworth H, Oddone E, Weinberger M (eds) Patient treatment adherence: concepts interventions, and measurement. Lawrence Erlbaum Associates, LondonGoogle Scholar
- DiMatteo M, Hays, RD, Gritz, ER, Bastani, R, Crane, L, Elashoff, R, & Marcus, A. (1993) Patient Adherence to Cancer Control Regimens: Scale Development and Initial Validation: Psychological AssessmentGoogle Scholar
- Heesen C, Bruce J, Feys P, Sastre-Garriga J, Solari A, Eliasson L, Matthews V, Hausmann B, Ross AP, Asano M, Imonen-Charalambous K, Köpke S, Clyne W, Bissell P (2014) Adherence in multiple sclerosis (ADAMS): classification, relevance, and research needs. A meeting report. In: Multiple sclerosis, vol 20, pp 1795–1798Google Scholar
- Jarmolowicz DP, Reed DD, Bruce AS et al (in press) Modeling effects of side-effect probability, side effect severity, and medication efficacy on patients with multiple sclerosis medication choice. Exp Clin PsychopharmacolGoogle Scholar
- Lezak M (1995) Neuropsychological assessment, third edn. Oxford University Press, New YorkGoogle Scholar
- Meredith SE, Petry NM (2017) Improving medication adherence with behavioral economics. In: Hanoch Y, Barnes A, Rice T (eds) Behavioral economics and healthy behaviors: Key concepts and current research. Routledge, NY, pp 109–126Google Scholar
- National Institute of Neurological Disorders and Stroke (2012) Multiple sclerosis: hope through research. Available at: www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Hope-Through-Research/Multiple-Sclerosis-Hope-Through-Research (accessed 31 August 2018)
- Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O'Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69:292–302CrossRefGoogle Scholar
- Wallin MT, Culpepper WJ, Coffman P, Pulaski S, Maloni H, Mahan CM, Haselkorn JK, Kurtzke JF, for the Veterans Affairs Multiple Sclerosis Centres of Excellence Epidemiology Group (2012) The Gulf War era multiple sclerosis cohort: age and incidence rates by race, sex and service. Brain 135:1778–1785CrossRefGoogle Scholar
- Wechsler D (1997) Wechsler adult intelligence scale—third edition. The Psychological Corporation, San AntonioGoogle Scholar
- World Health Organization (2003) Adherence to long-term tehrapies: evidence for action. Available at: www.who.int/chp/knowledge/publications/adherence_report/en/ (accessed 31 August 2018)